ANI Pharmaceuticals (NASDAQ:ANIP) Downgraded by BidaskClub to “Hold”

Share on StockTwits

BidaskClub cut shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a buy rating to a hold rating in a research report report published on Thursday, BidAskClub reports.

ANIP has been the topic of several other reports. Canaccord Genuity cut shares of Magellan Aerospace from a buy rating to a hold rating and dropped their target price for the stock from C$21.00 to C$20.00 in a report on Monday, May 13th. Zacks Investment Research cut shares of ExlService from a hold rating to a sell rating in a report on Wednesday. ValuEngine upgraded shares of Xylem from a hold rating to a buy rating in a report on Friday, June 21st. Raymond James reiterated a buy rating on shares of Canadian Natural Resources in a report on Friday, May 10th. Finally, Cantor Fitzgerald reiterated a buy rating and set a $27.00 target price on shares of Spero Therapeutics in a report on Thursday, May 9th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $84.50.

ANI Pharmaceuticals stock traded up $1.65 during midday trading on Thursday, hitting $81.53. 7,135 shares of the company’s stock were exchanged, compared to its average volume of 167,970. The company has a current ratio of 0.92, a quick ratio of 0.67 and a debt-to-equity ratio of 0.33. ANI Pharmaceuticals has a 12 month low of $36.92 and a 12 month high of $84.10. The business’s 50-day moving average price is $74.96. The firm has a market cap of $962.55 million, a P/E ratio of 17.86 and a beta of 2.25.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.25. ANI Pharmaceuticals had a net margin of 6.58% and a return on equity of 28.63%. The company had revenue of $52.90 million for the quarter, compared to analysts’ expectations of $50.57 million. During the same period in the prior year, the business earned $1.32 EPS. The firm’s quarterly revenue was up 13.8% on a year-over-year basis. As a group, sell-side analysts expect that ANI Pharmaceuticals will post 5.57 earnings per share for the current year.

In other news, Director Thomas Haughey purchased 2,500 shares of the firm’s stock in a transaction on Wednesday, May 15th. The stock was acquired at an average cost of $69.30 per share, with a total value of $173,250.00. Following the completion of the transaction, the director now owns 6,291 shares in the company, valued at approximately $435,966.30. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Robert W. Schrepfer sold 2,409 shares of the stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $71.13, for a total transaction of $171,352.17. Following the sale, the senior vice president now directly owns 55,927 shares of the company’s stock, valued at $3,978,087.51. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,911 shares of company stock valued at $3,585,114. Insiders own 24.70% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the business. Financial Gravity Wealth Inc. purchased a new stake in shares of ANI Pharmaceuticals during the first quarter valued at about $54,000. Quantamental Technologies LLC raised its position in shares of ANI Pharmaceuticals by 169.4% in the 1st quarter. Quantamental Technologies LLC now owns 862 shares of the specialty pharmaceutical company’s stock valued at $61,000 after purchasing an additional 542 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in shares of ANI Pharmaceuticals by 55,466.7% in the 1st quarter. BNP Paribas Arbitrage SA now owns 1,667 shares of the specialty pharmaceutical company’s stock valued at $118,000 after purchasing an additional 1,664 shares during the last quarter. Truvestments Capital LLC purchased a new position in shares of ANI Pharmaceuticals in the 1st quarter valued at approximately $140,000. Finally, BerganKDV Wealth Management LLC purchased a new position in shares of ANI Pharmaceuticals in the 1st quarter valued at approximately $141,000. 63.92% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Featured Article: Options Trading – Understanding Strike Price

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Madison Square Garden  PT Lowered to $362.00 at Imperial Capital
Madison Square Garden PT Lowered to $362.00 at Imperial Capital
Merus  Upgraded at BidaskClub
Merus Upgraded at BidaskClub
NVIDIA  Given Buy Rating at Benchmark
NVIDIA Given Buy Rating at Benchmark
Barclays Increases Medtronic  Price Target to $117.00
Barclays Increases Medtronic Price Target to $117.00
Ross Stores  Issues  Earnings Results
Ross Stores Issues Earnings Results
Citi Trends  Issues FY 2019 Earnings Guidance
Citi Trends Issues FY 2019 Earnings Guidance


 
© 2006-2019 Zolmax.